GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai HeartCare Medical Technology Corp Ltd (HKSE:06609) » Definitions » Cash Ratio

Shanghai HeartCare Medical Technology (HKSE:06609) Cash Ratio : 11.68 (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai HeartCare Medical Technology Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Shanghai HeartCare Medical Technology's Cash Ratio for the quarter that ended in Jun. 2024 was 11.68.

Shanghai HeartCare Medical Technology has a Cash Ratio of 11.68. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Shanghai HeartCare Medical Technology's Cash Ratio or its related term are showing as below:

HKSE:06609' s Cash Ratio Range Over the Past 10 Years
Min: 8.66   Med: 12.93   Max: 21.99
Current: 8.66

During the past 6 years, Shanghai HeartCare Medical Technology's highest Cash Ratio was 21.99. The lowest was 8.66. And the median was 12.93.

HKSE:06609's Cash Ratio is ranked better than
93.3% of 851 companies
in the Medical Devices & Instruments industry
Industry Median: 1.1 vs HKSE:06609: 8.66

Shanghai HeartCare Medical Technology Cash Ratio Historical Data

The historical data trend for Shanghai HeartCare Medical Technology's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai HeartCare Medical Technology Cash Ratio Chart

Shanghai HeartCare Medical Technology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Ratio
Get a 7-Day Free Trial 17.27 21.99 12.89 12.06 8.66

Shanghai HeartCare Medical Technology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 12.89 13.42 12.06 11.68 8.66

Competitive Comparison of Shanghai HeartCare Medical Technology's Cash Ratio

For the Medical Devices subindustry, Shanghai HeartCare Medical Technology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai HeartCare Medical Technology's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai HeartCare Medical Technology's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai HeartCare Medical Technology's Cash Ratio falls into.


;
;

Shanghai HeartCare Medical Technology Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Shanghai HeartCare Medical Technology's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=788.767/65.388
=12.06

Shanghai HeartCare Medical Technology's Cash Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash Ratio (Q: Jun. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=778.986/66.679
=11.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai HeartCare Medical Technology  (HKSE:06609) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Shanghai HeartCare Medical Technology Cash Ratio Related Terms

Thank you for viewing the detailed overview of Shanghai HeartCare Medical Technology's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai HeartCare Medical Technology Business Description

Traded in Other Exchanges
N/A
Address
No. 356, Zhengbo Road, Floor 1 and 3, Building 38, Pilot Free Trade Zone, Lingang New District, Shanghai, CHN
Shanghai HeartCare Medical Technology Corp Ltd is an innovative neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. Geographically, the Group's revenue is derived from Mainland China.
Executives
Ding Kui 2201 Interest of corporation controlled by you
Wisary Limited 2101 Beneficial owner
Li Jun 2201 Interest of corporation controlled by you
Shanghai Yuxinan Enterprise Management Co., Ltd. 2201 Interest of corporation controlled by you
Wang Guohui
Shanghai Zandaqian Enterprise Management Consulting Center
Lyfe Capital Management Limited
Lyfe Capital Fund Iii (dragon), L.p.
Shanghai Weiyun Enterprise Management Consulting Partnership (lp)
Lyfe Columbia River Limited
Temasek Holdings (private) Limited
Elbrus Investments Pte. Ltd.
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited

Shanghai HeartCare Medical Technology Headlines

No Headlines